BRAF and adenocarcinoma: Pathology for 25 patients (96.2%) in the wt-BRCA group revealed adenocarcinoma and 9 patients (34.6%) had additional mutations in actionable driver mutations (EGFR, ALK, BRAF, MET or ERBB2) (Table 1).